within Pharmacolibrary.Drugs.ATC.R;

model R06AA52
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.72,
    Cl             = 0.00015500000000000003,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0043,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R06AA52</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Diphenhydramine is a first-generation antihistamine primarily used for the temporary relief of symptoms due to hay fever, allergies, the common cold, and insomnia. When in combinations (such as with expectorants or decongestants), it is often used for symptomatic treatment of cold or allergy and sleep preparations. It is approved and widely used today, including over-the-counter formulations.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects following oral administration of diphenhydramine in combination products are based on extrapolation from available data on single-agent diphenhydramine. There are no published studies specifically reporting PK parameters for diphenhydramine in R06AA52 combination products.</p><h4>References</h4><ol><li><p>Ehling, S, et al., &amp; Papich, MG (2019). Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. <i>Veterinary dermatology</i> 30(2) 91–e24. DOI:<a href=\"https://doi.org/10.1111/vde.12727\">10.1111/vde.12727</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30779257/\">https://pubmed.ncbi.nlm.nih.gov/30779257</a></p></li><li><p>Gilbert, JD, et al., &amp; Draffan, GH (1984). The pharmacokinetics of meprobamate following its oral and rectal administration as a series of combinations with diphenhydramine, acetylsalicylic acid, codeine and pentaerythritol tetranitrate. <i>Arzneimittel-Forschung</i> 34(10) 1323–1327. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6549136/\">https://pubmed.ncbi.nlm.nih.gov/6549136</a></p></li><li><p>Knowles, S, et al., &amp; Shear, NH (1994). Metronidazole hypersensitivity. <i>The Annals of pharmacotherapy</i> 28(3) 325–326. DOI:<a href=\"https://doi.org/10.1177/106002809402800305\">10.1177/106002809402800305</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8193418/\">https://pubmed.ncbi.nlm.nih.gov/8193418</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R06AA52;
